Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells

Journal of Cellular Physiology

Volumn 201, Issue 3, 2004, Pages 374-384

  Nomura, Motohiro ^a   Nomura, Naoko ^a   Newcomb, Elizabeth W ^a,b   Lukyanov, Yevgeniy ^a   Tamasdan, Cristina ^a   Zagzag, David ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 3; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; GELDANAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL CYCLE PHASE; CELL DEATH; CELL PROLIFERATION; CELL SYNCHRONIZATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROMES C; FLAVOPROTEINS; GLIOMA; HUMANS; LACTAMS, MACROCYCLIC; MEMBRANE PROTEINS; MITOCHONDRIA; MITOSIS; QUINONES;

EID: 7544243762     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20090     Document Type: Article

References (51)

1. Alonso M, Tamasdan C, Miller DC, Newcomb EW. 2003. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2:139-150.
2. Arnoult D, Parone P, Martinou JC, Antonsson B, Estaquier J, Ameisen JC. 2002. Mitochondrial release of apopotosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 159:923-929.
3. Asselin E, Mills GB, Tsang BK. 2001. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61:1862-1868.
4. Becker J, Craig EA. 1994. Heat-shock proteins as molecular chaperones. Eur J Biochem 219:11-23.
5. Bible KC, Kaufman SH. 1997. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res 57:3375-3380.
6. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. 1996. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 93:8379-8383.
7. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. 2001. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 15:1537-1543.
8. Brugge JS, Erikson E, Erikson RL. 1981. The specific interaction of the Rous sarcoma virus transforming protein, pp60src, with two cellular proteins. Cell 25:363-372.
9. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746.
10. Coumailleau P, Poellinger L, Gustafsson JA, Whitelaw ML. 1995. Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity. J Biol Chem 270:25291-25300.
11. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. 1992. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613-619.
12. Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WKA. 2001. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 61:6693-6697.
13. Gradin K, McGuire J, Wenger RH, Kvietikova I, fhitelaw ML, Toftgard R, Tora L, Gassmann M, Poellinger L. 1996. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16:5221-5231.
14. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO. 1997. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850.
15. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. 2001. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009.
16. Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B. 2002. Mitochondrial dysfunction is an essential step for killing of non-small lung carcinomas resistant to conventional treatment. Oncogene 21:65-77.
17. Kim S, Kang J, Hu W, Evers BM, Chung DH. 2003. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 103:352-359.
18. Kumar AP, Garcia GE, Slaga TJ. 2001. 2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 31:111-124.
19. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R. 2003. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154.
20. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. 2001. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15:1311-1333.
21. Mercer WE. 1998. Checking on the cell cycle. J Cell Biochem Suppl 30-31:50-54.
22. Mimnaugh EG, Chavany C, Neckers L. 1996. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-22801.
23. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM. 2002. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735-2741.
24. Neckers L. 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:55-61.
25. Nguyen DM, Chen A, Mixon A, Schrump DS. 1999. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J Thorac Cardiovasc Surg 118:908-915.
26. Nimmanapalli R, O'Bryan E, Bhalla K. 2001. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799-1804.
27. Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Dun QY, Clark OH. 2003. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88:3346-3353.
28. Penninger J, Kroemer G. 2000. Mitochondria, AIF and caspases - Rivaling for cell death execution. Nat Cell Biol 5:97-99.
29. Ruth AC, Roninson IB. 2000. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 60:2576-2578.
30. Sanchez ER, Toft DO, Schlesinger MJ, Pratt WB. 1985. Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptor is a murine heat shock protein. J Biol Chem 260:12398-12401.
31. Sato S, Fujita N, Tsuruo T. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837.
32. Schlegel J, Piontek G, Budde B, Neff F, Kraus A. 2000. The Akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme. Cancer Lett 158:103-108.
33. Schmid I, Uittenbogaart CH, Giorgi JV. 1994. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry 15:12-20.
34. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al. 1995. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806-3812.
35. Schulte TW, An WG, Neckers LM. 1997. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239:655-659.
36. Shaknovich R, Shue G, Kohtz DS. 1992. Conformational activation of a basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine HSP90 (HSP84). Mol Cell Biol 12:5059-5068.
37. Shtivelman E, Sussman J, Stokoe D. 2002. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 12:919-924.
38. 1 arrest. Cancer Res 60:3940-3946.
39. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB. 1993. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 268:21711-21716.
40. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. 1997. Crystal structure of an Hsp90-geldanamycin complex; Targeting of a protein chaperone by an antitumor agent. Cell 89:239-250.
41. 1 arrest in vivo. J. Cell Physiol 99:43-54.
42. Takahashi Y, Rayman JB, Dynlacht BD. 2000. Analysis promoter binding by the E2F and pRB families in vivo: Distinct E2F proteins mediate activation and repression. Genes Dev 14:804-816.
43. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, Dichgans J. 1998. Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int J Cancer 79:640-644.
44. Whitesell L, Shifrin SD, Schwab G, Neckers LM. 1992. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 52:1721-1728.
45. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role or stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328.
46. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. 1997. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14:2809-2816.
47. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L. 2001. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276:3702-3708.
48. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. 2001. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61:1029-1037.
49. Yu S-W, Wang J, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirer GG, Dawson TM, Dawson VL. 2002. Mediation of poly(ADP-ribose polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297:259-263.
50. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, Newcomb EW. 2003. Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196:394-402.
51. Zhou H, Li XM, Meinkoth J, Pittman RN. 2000. Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483-494.